Wang Q, Greene M
Cancers (Basel). 2024; 16(9).
PMID: 38730657
PMC: 11083197.
DOI: 10.3390/cancers16091705.
Fung S, Knoefel W, Krieg A
Cancers (Basel). 2021; 13(16).
PMID: 34439255
PMC: 8392569.
DOI: 10.3390/cancers13164098.
Li D, Hu C, Li H
Biomed Rep. 2018; 8(5):399-406.
PMID: 29725522
PMC: 5920485.
DOI: 10.3892/br.2018.1077.
Winther T, Torp S
PLoS One. 2017; 12(9):e0185217.
PMID: 28953948
PMC: 5617184.
DOI: 10.1371/journal.pone.0185217.
Liu S, Shi L, Yang X, Ye D, Wang T, Dong C
Cell Cycle. 2017; 16(9):894-902.
PMID: 28384094
PMC: 5444357.
DOI: 10.1080/15384101.2017.1310352.
Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Hong J, Ryu K, Park C, Hong M, Ko Y, Kim W
Oncotarget. 2017; 8(8):13782-13791.
PMID: 28099151
PMC: 5355138.
DOI: 10.18632/oncotarget.14636.
Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.
Bresler S, Min L, Rodig S, Walls A, Xu S, Geng S
Lab Invest. 2016; 97(2):207-216.
PMID: 27918555
DOI: 10.1038/labinvest.2016.126.
Expression of hypoxia-inducible factor-1α affects tumor proliferation and antiapoptosis in surgically resected lung cancer.
Takasaki C, Kobayashi M, Ishibashi H, Akashi T, Okubo K
Mol Clin Oncol. 2016; 5(2):295-300.
PMID: 27446567
PMC: 4950225.
DOI: 10.3892/mco.2016.937.
Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.
Duan L, Hu X, Jin Y, Liu R, You Q
BMC Cancer. 2016; 16:276.
PMID: 27090386
PMC: 4836165.
DOI: 10.1186/s12885-016-2304-3.
Serum survivin increases in prolactinoma.
Dellal F, Niyazoglu M, Gorar S, Ademoglu E, Candan Z, Bekdemir H
J Clin Med Res. 2015; 7(4):248-52.
PMID: 25699121
PMC: 4330017.
DOI: 10.14740/jocmr2098w.
Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.
Wu Y, Huang C, Yang M, Lan C, Lee C, Chan E
Med Oncol. 2014; 31(8):79.
PMID: 24961465
DOI: 10.1007/s12032-014-0079-4.
Association of cigarette smoking with the expression of nuclear survivin in pathological Stage IA lung adenocarcinomas.
Hirano H, Maeda H, Takeuchi Y, Susaki Y, Kobayashi R, Hayashi A
Med Mol Morphol. 2013; 47(4):196-200.
PMID: 24213518
DOI: 10.1007/s00795-013-0061-9.
Nuclear survivin and its relationship to DNA damage repair genes in non-small cell lung cancer investigated using tissue array.
Hu S, Qu Y, Xu X, Xu Q, Geng J, Xu J
PLoS One. 2013; 8(9):e74161.
PMID: 24066112
PMC: 3774659.
DOI: 10.1371/journal.pone.0074161.
Targeting survivin in cancer: novel drug development approaches.
Groner B, Weiss A
BioDrugs. 2013; 28(1):27-39.
PMID: 23955284
PMC: 3929033.
DOI: 10.1007/s40259-013-0058-x.
Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma.
Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S
Virchows Arch. 2012; 462(1):101-7.
PMID: 23179762
DOI: 10.1007/s00428-012-1343-7.
Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies.
Huang L, Wang D, Chen Y, Zhao C, Gong B, Jiang A
Mol Biol Rep. 2012; 40(2):917-24.
PMID: 23065255
DOI: 10.1007/s11033-012-2132-8.
Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.
Kobayashi M, Huang C, Sonobe M, Kikuchi R, Ishikawa M, Kitamura J
Exp Ther Med. 2012; 3(6):952-958.
PMID: 22969998
PMC: 3438599.
DOI: 10.3892/etm.2012.511.
Poor Prognostic Factors in Surgically Resected Stage I Non-small Cell Lung Cancer: Histopathologic and Immunohistochemical Analysis.
Cho S, Park T, Lee E, Son S
Korean J Thorac Cardiovasc Surg. 2012; 45(2):101-9.
PMID: 22500280
PMC: 3322179.
DOI: 10.5090/kjtcs.2012.45.2.101.
Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis.
Zhang L, Wang J, Jiang F, Xu L, Liu F, Yin R
PLoS One. 2012; 7(3):e34100.
PMID: 22457815
PMC: 3311582.
DOI: 10.1371/journal.pone.0034100.
Survivin in solid tumors: rationale for development of inhibitors.
Church D, Talbot D
Curr Oncol Rep. 2012; 14(2):120-8.
PMID: 22234703
DOI: 10.1007/s11912-012-0215-2.